Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-NODAGA-MUC1-FA
- Development stage
- Preclinical
- Lead developer
- King Faisal Specialist Hospital and Research Centre
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
68Ga-NODAGA-MUC1-FA is a novel radiolabeled hybrid peptide conjugate designed for positron emission tomography (PET) imaging of epithelial cancers, particularly breast and ovarian cancers. It consists of a Mucin-1 (MUC1)-derived peptide conjugated to folic acid (FA) via a terminal lysine residue, and chelated with gallium-68 (68Ga) using the bifunctional chelator NODAGA. This hybrid conjugate is designed to dual-target MUC1 and folate receptors, which are highly overexpressed in epithelial malignancies but have low expression in normal tissues. Preclinical evaluations in mouse models have demonstrated rapid blood clearance, predominant urinary excretion, and significant tumor uptake, suggesting its potential as a molecular probe for early detection, staging, and monitoring of treatment response in MUC1- and folate receptor-positive cancers.
- Other names
- 68Ga-NODAGA-MUC1-FA hybrid peptide conjugateGa-68-NODAGA-MUC1-FAGa68-NODAGA-MUC1-FAGa 68-NODAGA-MUC1-FAgallium Ga 68 NODAGA-MUC1-FA
02
Targets
FOLR1 (FRα)MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on 68Ga-NODAGA-MUC1-FA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-NODAGA-MUC1-FA.